IGC Pharma (IGC) Assets Average (2011 - 2026)

IGC Pharma (IGC) has reported Assets Average for 16 consecutive years, with $9.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Assets Average rose 6.01% year-over-year to $9.4 million in Q1 2026; TTM through Mar 2026 was $9.4 million, a 6.01% increase from a year earlier, with the FY2026 full-year figure at $9.0 million, down 3.84% from the prior year.
• Assets Average was $9.4 million for Q1 2026 at IGC Pharma, down from $9.7 million in the prior quarter.
• Over five years, Assets Average peaked at $29.1 million in Q1 2022 and troughed at $8.3 million in Q2 2025.
• A 5-year average of $14.7 million and a median of $10.6 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average tumbled 43.19% in 2024 and rose 6.01% in 2026, its largest moves.
• Over 5 years, Assets Average stood at $21.0 million in 2022, then tumbled by 33.94% to $13.9 million in 2023, then dropped by 29.96% to $9.7 million in 2024, then rose by 0.04% to $9.7 million in 2025, then slipped by 2.87% to $9.4 million in 2026.
• The last three Assets Average figures came in at $9.4 million (Q1 2026), $9.7 million (Q4 2025), and $8.8 million (Q3 2025), per Business Quant data.